Excess of deaths for patients with plasma cell proliferative disorders as a result of the COVID-19 pandemic.

Dunne, Tom; Stewart, Douglas; Lee, Holly; Tay, Jason; Duggan, Peter; McCulloch, Sylvia; Neri, Paola; Bahlis, Nizar J; Jimenez-Zepeda, Victor H

Dunne, Tom; Stewart, Douglas; Lee, Holly; Tay, Jason; Duggan, Peter; McCulloch, Sylvia; Neri, Paola; Bahlis, Nizar J; Jimenez-Zepeda, Victor H.

Afiliação

Dunne T; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada.
Stewart D; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada.
Lee H; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada.
Tay J; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada.
Duggan P; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada.
McCulloch S; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada.
Neri P; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada.
Bahlis NJ; Charbonneau Cancer Research Institute, Calgary, Canada.
Jimenez-Zepeda VH; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, Canada.

Leuk Lymphoma ; 62(14): 3555-3557, 2021 12.

Article em En | MEDLINE | ID: mdl-34435538

Assuntos

COVID-19; Humanos; Pandemias; Plasmócitos; SARS-CoV-2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google